Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NC525 |
Synonyms | |
Therapy Description |
NC525 is a monoclonal antibody that targets LAIR1 expressed on tumor cells, potentially leading to decreased tumor growth (Blood (2022) 140 (Supplement 1): 9078-9079). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NC525 | NC-525|NC 525 | NC525 is a monoclonal antibody that targets LAIR1 expressed on tumor cells, potentially leading to decreased tumor growth (Blood (2022) 140 (Supplement 1): 9078-9079). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05787496 | Phase I | NC525 | A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms | Active, not recruiting | USA | 0 |